INmune Bio Inc.

NASDAQ: INMB · Real-Time Price · USD
2.53
0.08 (3.27%)
At close: Aug 15, 2025, 3:59 PM
2.47
-2.37%
After-hours: Aug 15, 2025, 07:51 PM EDT

INmune Bio Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a 50K n/a n/a n/a 14K 28K 43K 46K 38K 97K 98K 16K 163K 163K 14K n/a 4K
Cost of Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
n/a 50K n/a n/a n/a 14K 28K 43K 46K 38K 97K 98K 16K 163K 163K 14K n/a 4K
Operating Income
-24.57M -9.9M -9.47M -12.29M -9.87M -11.02M -8.38M -8.53M -6.41M -6.42M -5.64M -7.44M -6.39M -6.48M -9.03M -9.02M -6.55M -4.55M
Interest Income
n/a n/a n/a n/a n/a n/a n/a 568K 631K 612K 1.42M 525K n/a n/a n/a n/a n/a n/a
Pretax Income
-24.46M -9.74M -9.22M -12.09M -9.75M -11.03M -8.41M -8.56M -6.5M -6.54M -5.83M -7.72M -6.84M -6.9M -9.67M -9.46M -6.66M -4.56M
Net Income
-24.46M -9.74M -9.22M -12.09M -9.75M -11.03M -8.41M -8.56M -6.5M -6.65M -6.02M -8.01M -7.29M -7.33M -9.67M -9.46M -6.66M -4.56M
Selling & General & Admin
2.25M 2.32M 2.11M 2.22M 2.81M 2.34M 2.4M 2.59M 2.31M 2.33M 2.33M 2.38M 2.21M 2.33M 2.13M 2.52M 2.09M 2.06M
Research & Development
5.8M 7.64M 7.35M 10.07M 7.05M 8.69M 6.01M 5.99M 4.15M 4.13M 3.41M 5.16M 4.19M 4.31M 7.07M 6.52M 4.46M 2.49M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -8K
Operating Expenses
8.06M 9.96M 9.47M 12.29M 9.87M 11.03M 8.41M 8.57M 6.46M 6.46M 5.74M 7.54M 6.4M 6.64M 9.19M 9.04M 6.55M 4.55M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a 113K 191K 282K 450K 425K 21.31M n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a 41K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
8.06M 9.96M 9.47M 12.29M 9.87M 11.03M 8.41M 8.57M 6.46M 6.46M 5.74M 7.54M 6.4M 6.64M 9.19M 9.04M 6.55M 4.55M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a 113K 191K 282K 450K 425K n/a n/a n/a n/a
Shares Outstanding (Basic)
23.3M 22.5M 22.28M 20.19M 19.31M 18.03M 17.95M 18.01M 17.95M 17.95M 17.93M 17.95M 17.95M 17.87M 17.33M 17.33M 14.97M 14.32M
Shares Outstanding (Diluted)
23.3M 22.5M 22.28M 20.19M 19.31M 18.03M 17.95M 18.01M 17.95M 17.95M 17.93M 17.95M 17.95M 17.87M 17.33M 17.33M 14.97M 14.32M
EPS (Basic)
-1.05 -0.43 -0.41 -0.6 -0.5 -0.61 -0.47 -0.48 -0.36 -0.37 -0.34 -0.45 -0.41 -0.41 -0.56 -0.55 -0.44 -0.32
EPS (Diluted)
-1.05 -0.43 -0.41 -0.6 -0.5 -0.61 -0.47 -0.48 -0.36 -0.37 -0.34 -0.45 -0.41 -0.41 -0.56 -0.55 -0.44 -0.32
EBITDA
-24.57M -9.9M -9.22M -12.29M -9.87M -11.02M -8.38M -8.53M -6.41M -6.42M -5.64M -7.44M -6.39M -6.48M -9.03M -9.02M -6.55M -4.55M
EBIT
-24.46M -9.9M -9.22M -12.29M -9.87M -11.03M -8.41M -8.53M -6.41M -6.42M -5.83M -7.44M -6.39M -6.9M -9.67M -9.46M -6.66M -4.56M
Depreciation & Amortization
n/a n/a n/a n/a 9.87M n/a n/a 8.53M 6.41M 6.42M 5.64M 7.44M 6.39M 6.48M 9.03M 9.02M 6.55M 4.55M